@legalmiga's Ozempic to Zepbound switch, fact-checked

What did @legalmiga actually say?

Fred, a postpartum creator three months out from delivery, shared that she took semaglutide (Ozempic) before pregnancy to prepare her body, gained roughly 50-55 pounds during pregnancy, retained about 40 of those pounds, and is now starting tirzepatide (Zepbound) at 2.5mg weekly. She described feeling nausea within 24 hours of her first Zepbound dose, which surprised her given that she barely felt Ozempic's effects for the first month. She also said, "Ozempic was for diabetes prescribed for weight loss" and that "Zepbound is specifically for weight loss." She was transparent about her family history of diabetes, her pre-diabetic status before pregnancy, and her gestational diabetes diagnosis, framing GLP-1 use as a preventive health decision rather than purely cosmetic.

Does the science back this up?

Mostly yes, with some important nuances. The distinction she draws between the two drugs is directionally correct but oversimplified. The nausea timeline she describes is also plausible and supported by pharmacokinetic data.

Tirzepatide (Zepbound) received FDA approval specifically for chronic weight management in adults with obesity or overweight with a weight-related condition in November 2023. Semaglutide as Ozempic is FDA-approved for type 2 diabetes; its sister drug Wegovy carries the obesity indication. That said, off-label prescribing of Ozempic for weight loss is legal and common. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at 15mg produced 20.9% mean body weight reduction, outperforming semaglutide data from the STEP-1 trial (Wilding et al., 2021, NEJM). On nausea: tirzepatide's dual GIP/GLP-1 mechanism means GI side effects can appear early, consistent with what Fred experienced. Her gestational diabetes history placing her at higher T2D risk is well-documented, with studies showing roughly 50% of women with GDM develop T2D within 10 years (Bellamy et al., 2009, Lancet).

What did they get wrong (or right)?

Fred gets credit for being transparent about her actual medical rationale, consulting doctors both times, and not overselling results. She correctly identified that her GDM history raises her future diabetes risk, and she was appropriately hedged, saying "I'm not a doctor."

Where she slips: the claim that Ozempic "was for diabetes prescribed for weight loss" frames off-label use as if it's the drug's secondary function, which isn't quite right. Ozempic's approved indication is glycemic control in type 2 diabetes. Wegovy, the same molecule at a higher dose, is the weight-loss-approved version. They are not the same product prescribed differently. This matters because insurers, pharmacies, and regulators treat them as distinct. She also assumes her stronger nausea response this time means she's "responding well," which is a leap. Nausea severity doesn't reliably predict weight-loss efficacy. Early GI side effects often reflect GI sensitivity, not metabolic response. Patients who drop out of trials due to nausea don't lose more weight because of it.

What should you actually know?

If you're postpartum, the timing question around GLP-1 drugs is real and under-discussed. Current guidance from the Obesity Society and most prescribing clinicians suggests waiting until breastfeeding is complete, since GLP-1 receptor agonists have not been studied in lactating women and animal data show transfer into milk. Fred mentions her baby is three months old but does not clarify whether she is breastfeeding. That gap matters clinically.

The GDM-to-T2D risk she describes is not hypothetical. Bellamy et al. found a sevenfold increased risk of T2D in women with prior GDM compared to those without. GLP-1 agonists have shown benefit in delaying T2D onset in high-risk populations, as shown in the SCALE Obesity and Prediabetes trial (le Roux et al., 2017, Lancet). Her framing of these drugs as preventive is supported, but prevention claims require a doctor's individualized assessment, not a TikTok video.

• Zepbound and Ozempic are not interchangeable products. They work differently (dual vs. single receptor agonism) and carry different FDA indications.
• Nausea on day two of tirzepatide is common and does not predict how well the drug will work for you.
• Postpartum GLP-1 use requires specific clinical consideration, particularly around breastfeeding status.

Bottom line

Fred's video is more medically grounded than most GLP-1 content on TikTok. She's not selling anything, she consulted physicians, and her risk framing is legitimate. The drug distinction she makes is slightly off, and her interpretation of nausea as a positive signal isn't backed by evidence. But the core message, that GLP-1 drugs used responsibly under medical supervision can serve a real preventive function in high-risk patients, is defensible.